Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers

Human Psychopharmacology

Volumn 21, Issue 8, 2006, Pages 549-559

  Penetar, David M ^a   Looby, Alison R ^a   Su, Zhaohui ^b   Lundahl, Leslie H ^a,c   Erös Sarnyai, Monika ^a,d   McNeil, Jane F ^a   Lukas, Scott E ^a  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Health and Mental Hygiene ^*  (United States)

Author keywords

Benztropine; Cocaine; Pharmacotherapy; Physiological effects; Visual analog scales

Indexed keywords

BENZATROPINE MESILATE; COCAINE; PLACEBO; RECREATIONAL DRUG;

ARTICLE; COCAINE DEPENDENCE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG SELF ADMINISTRATION; DYSPHORIA; EUPHORIA; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PUPIL; SELF REPORT; SKIN TEMPERATURE; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE; VOLUNTEER;

ADULT; BENZTROPINE; BLOOD PRESSURE; COCAINE; COCAINE-RELATED DISORDERS; DATA INTERPRETATION, STATISTICAL; ELECTROCARDIOGRAPHY; EUPHORIA; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; MUSCARINIC ANTAGONISTS; PUPIL; SKIN TEMPERATURE;

EID: 33846055420     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.810     Document Type: Article

References (52)

1. 3H]GBR12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J Neurochem 48: 1887-1896.
2. Baumann MH, Char GU, De Costa BR, Rice KC, Rothman RB. 1994. GBR 12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271: 1216-1222.
3. Berger P, Gawin F, Kosten TR. 1989. Treatment of cocaine abuse with mazindol. Lancet 333: 283.
4. Carroll FI, Howell LL, Kuhar MJ. 1999. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42: 2721-2736.
5. Chamberlain DA, Turner P, Sneddon JM. 1967. Effects of atropine on heart rate in healthy man. Lancet 2: 12-15.
6. Cone EJ, Hillsgrove M, Darwin WD. 1994. Simultaneous measurement of cocaine, cocaethylene, their metabolites, and "crack" pyrolysis products by gas chromatography-mass spectrometry. Clin Chem 40: 1299-1305.
7. Dar DE, Mayo C, Uhl GR. 2005. The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol 70: 461-469.
8. Desai RI, Kopajtic TA, French D, Newman AH, Katz JL. 2005a. Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}- 4-(3-phenylpropyl)-piperazine], and benztropine analogs. J Pharmacol Exp Ther 315: 397-404.
9. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL. 2005b. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889-1893.
10. Dworkin SI, Pitts RC. 1994. Use of rodent self-administration models to develop pharmacotherapies for cocaine abuse. In Neurobiological Models for Evaluating Mechanisms Underlying Cocaine Addiction, Erinoff L, Brown RM (eds.). NIDA Research Monograph 145, NIH Publication No. 94-3600. US Government Printing Office: Washington DC; 88-112.
11. Dworkin SI, Lambert P, Sizemore GM, Carroll FI, Kuhar MJ. 1998. RTI-113 administration reduces cocaine self-administration at high occupancy of dopamine transporter. Synapse 30: 49-55.
12. Esplin DW 1970. Centrally acting muscle relaxants; drugs for Parkinson's disease. In The Pharmacological Basis of Therapeutics, 4th edn, Goodman LS, Gilman A (eds.). Macmillan: New York; 226-236.
13. Glowa JR, Wojnicki FHE, Matecka D, Bacher JD. 1995. Effects of dopamine reuptake inhibitors on food- and cocaine-maintained responding: I. Dependence on unit dose of cocaine. Exp Clin Psychopharmacol 3: 219-231.
14. Katz JL, Agoston GE, Alling KL, Kline RH, Forster MJ, Woolverton WL, Kopajtic TA, Newman AH, 2001. Dopamine transporter binding without cocaine-like behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents. Psychopharmacology 154: 362-374.
15. Katz JL, Izenwasser S, Kline RH, Allen AC, Newman AH. 1999. Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288: 302-315.
16. Katz JL, Newman AH, Izenwasser S. 1997. Relations between heterogeneity of dopamine transporter binding and function and the behavioral pharmacology of cocaine. Pharmacol Biochem Behav 57: 505-512.
17. Kleven MS, Woolverton WL. 1993. Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend 31: 149-158.
18. Kline RH, Izenwasser S, Katz JL, Joseph DB, Brwen WD, Newman AH. 1997. 3′-Chloro-3α-(diphenylmethoxy)tropane but not 4′-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem 40: 851-857.
19. Kulkarni SS, Grundt P, Kopajtic T, Katz JL, Newman AH. 2004. Structure-activity relationships at monamine transporters for a series of N-substituted 3α-(Bis[4-flourophenyl]methoxy) tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation. J Med Chem 47: 3388-3398.
20. Kulkarni SS, Kopajtic TA, Katz JL, Newman AH. 2006. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorganic Med Chem 14: 3625-3634.
21. Li SM, Newman AH, Katz JL. 2005. Place conditioning and locomotor effects of N-substituted, 4′,4″-difluorobenztropine analogs in rats. J Pharmacol Exp Ther 313: 1223-1230.
22. Lindsey KP, Wilcox KM, Votaw JR, Goodman MM, Plisson C, Carroll FI, Rice KC, Howell LL. 2004. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther 309: 959-969.
23. Lukas SE, Mendelson JH, Benedikt RA. 1986a. Instrumental analysis of ethanol-induced intoxication in human males. Psychopharmacology 89: 8-13.
24. Lukas SE, Mendelson JH, Benedikt RA, Jones B. 1986b. EEG, physiologic and behavioral effects of ethanol administration. In Problems of Drug Dependence, 1985 NIDA Research Monograph 67, DHHS Publication No. (ADM) 86-1448, Harris LS (ed.). US Government Printing Office: Washington, DC; 209-214.
25. Lukas SE, Sholar M, Kouri E, Fukuzako H, Mendelson JH. 1994. Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers. Pharmacol Biochem Behav 48: 715-721.
26. Lukas S, Sholar M, Lundahl L, Lamas X, Kouri E, Wines J, Kragie L, Mendelson JH. 1996. Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Psychopharmacology 125: 346-354.
27. Martin WR, Sloan JW, Sapira JD, Jasinski DR. 1971. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
28. Newman AH, Agoston GE. 1998. Novel benztropine [3alpha-(diphenylmethoxy)tropane] analogs as probes for the dopamine transporter. Curr Med Chem 5: 305-319.
29. Newman AH, Allen AC, Izenwasser S, Katz JL. 1994. Novel 3alpha-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J Med Chem 37: 2258-2261.
30. Penetar DM, Henningfield JE. 1985. Psychoactivity of atropine in normal volunteers. Pharmacol Biochem Behav 24: 1111-1113.
31. Penetar DM, Haegerstrom-Portnoy G, Jones RT. 1988. Combined atropine & 2-PAM Cl effects on tracking performance and visual, physiological, and psychological functions. Aviat Space Environ Med 59: 1125-1132.
32. Physicians' Desk Reference. 2005. 59th edn. Thomson PDR: Montvale, NJ; 2006-2007.
33. Preston KL, Sullivan JT, Berger P, Bigelow GE. 1993. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther 267: 296-307.
34. Ranaldi R, Woolverton WL. 2002. Self-administration of cocaine: scopolamine combinations by rhesus monkeys. Psychopharmacology 161: 442-448.
35. Reith MEA, Berfield JL, Wang LC, Ferrer JV, Javitch JA. 2001. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276: 29012-29018.
36. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223.
37. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. 1988. Cocaine self-administration appears to be mediated by dopamine uptake inhibition. Prog Neuro-Psychopharmacol Biol Psychiatry 12: 233-239.
38. Rothman RB. 1990. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 46: PL17-21.
39. Rothman RB, Glowa JR. 1995. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implication for medication development. Focus on GBR 12909. Mol Neurobiol 11: 1-19.
40. Rothman RB, Mele A, Reid A, Akunne H, Greig N, Thurkauf A, Rice K, Pert A. 1989. Tight binding dopamine reuptake inhibitors as cocaine antagonists: a strategy for drug development. FEBS Lett 257: 341-344. [published erratum in FEBS Letters, 1990, 260:152].
41. Rothman RB, Mele A, Reid AA, Akune HA, Greig N, Thurkauf A, deCosta BR, Rice KC, Pert A. 1991. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav 40: 387-397.
42. Schenk S. 2002. Effects of GBR 12909, WIN 35,428 and indatraline on cocaine self-administration and cocaine seeking in rats. Psychopharmacology 160: 263-270.
43. Simoni D, Rossi M, Bertolasi V, Roberti M, Pizzirani D, Rondanin R, Baruchello R, Invidiata FP, Tolomeo M, Grimaudo S, Merighi S, Varani K, Gessi S, Borea PA, Marino S, Cavallini S, Bianchi C, Siniscalchi A. 2005. Synthesis and pharmacology of 6-substituted benztropines: discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter. J Med Chem 48: 3337-3343.
44. Skjodager P, Winger G, Woods JH. 1993. Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys. Drug Alcohol Depend 33: 31-39.
45. Standaert DG, Young AB. 2001. Treatment of central nervous system degenerative disorders. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn, Hardman JG, Limbird LE, Gilman AG (eds.). McGraw Hill: New York; 549-568.
46. Stine SM, Krystal JH, Kosten TR, Charney DS. 1995. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 39: 245-252.
47. Tolliver B, Newman A, Katz J, Ho L, Fox L, Hsu K, Berger S. 1999. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo. J Pharmacol Exp Ther 289: 110-122.
48. Ukario OT, Bondi CD, Newman AH, Kulkarni SS, Kozikowski AP, Pan S, Surratt CK. 2005. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methyphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther 314: 575-583.
49. Wong DF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, Chan B, Folio T, Scheffel U, Ricaurte GA. 1993. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse 15: 130-142.
50. Woolverton WL, Johnson KM. 1992. Neurobiology of cocaine abuse. Trends Pharmacol Sci 13: 193-200.
51. Woolverton WL, Hecht GS, Agoston GE, Katz JL, Newman AH. 2001. Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology 154: 375-382.
52. Woolverton WL, Rowlett JK, Wilcox KM, Paul IA, Kline RH, Newman AH, Katz JL. 2000. 3′- and 4′-chloro-substituted analogs of benztropine: intravenous self-administration and in vitro radioligand binding studies in rhesus monkeys. Psychopharmacology 147: 426-435.